长期口服核苷(酸)类似物治疗慢性乙型肝炎不增加癌症风险——一项44 494名受试者的队列研究
基于香港医院管理局数据库的全区队列研究纳入44 494例慢性乙型肝炎患者(39 712例未治疗、4 782例治疗),随访194 890人年。倾向评分加权后,治疗组与未治疗组所有恶性肿瘤风险相似(加权风险比1.01,95%CI 0.82-1.25,P=0.899)。口服核苷(酸)类似物治疗似乎不增加慢性乙型肝炎患者的癌症风险,鉴于对肝脏结局的益处,数据支持当前长期抗病毒治疗的实践。
要点
- 倾向评分加权后,治疗组与未治疗组所有恶性肿瘤风险相似(加权风险比1.01,95%CI 0.82-1.25,P=0.899)。
- 治疗组与未治疗组肺癌/胸膜癌风险相似(加权风险比0.82,95%CI 0.52-1.31,P=0.409)。
- 治疗组与未治疗组泌尿/肾恶性肿瘤风险相似(加权风险比1.04,95%CI 0.38-2.81,P=0.944)。
核心结论
- 口服核苷(酸)类似物治疗似乎不增加慢性乙型肝炎患者的癌症风险;鉴于对肝脏结局的益处,数据支持当前长期抗病毒治疗的实践。
研究设计与样本
- 研究利用香港医院管理局数据库开展全区队列研究,依据2000年至2012年间的ICD-9-CM诊断编码确定慢性乙型肝炎和各种恶性肿瘤。
- 共纳入44 494例患者(39 712例未治疗和4 782例治疗),采用3年landmark分析,随访至7年,评估治疗与未治疗患者的癌症相对风险。
主要发现
- 随访194 890人年期间,未治疗组有402例(1.0%)发生肝细胞癌,治疗组有179例(3.7%)发生肝细胞癌;其他癌症分别有528例(1.3%)和128例(2.7%)发生。
- 倾向评分加权后,治疗组与未治疗组所有恶性肿瘤风险相似(加权风险比1.01,95%CI 0.82-1.25,P=0.899)。
- 倾向评分加权后,治疗组与未治疗组肺癌/胸膜癌风险相似(加权风险比0.82,95%CI 0.52-1.31,P=0.409)。
- 倾向评分加权后,治疗组与未治疗组泌尿/肾恶性肿瘤风险相似(加权风险比1.04,95%CI 0.38-2.81,P=0.944)。
临床怎么用
- 作者认为,鉴于对肝脏结局的益处,数据支持当前长期抗病毒治疗的实践。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with chronic hepatitis B (CHB) need long-term antiviral treatment with nucleos(t)ide analogues (NA). Animal studies suggest that some NA may increase cancer risk, but human data are lacking. AIM: To investigate cancer risks in patients with or without NA treatment. METHODS: We conducted a territory-wide cohort study using the database from Hospital Authority in Hong Kong. The diagnosis of CHB and various malignancies was based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes between 2000 and 2012. Patients exposed to any of the oral NA for CHB were included. The primary outcome was incident cancers. A 3-year landmark analysis, with follow-up up to 7 years, was used to evaluate the relative risk of cancers in treated and untreated patients. RESULTS: A total of 44 494 patients (39 712 untreated and 4782 treated) were included in the analysis. During 194 890 patient-years of follow-up, hepatocellular carcinoma developed in 402 (1.0%) untreated patients and 179 (3.7%) treated patients, while other cancers developed in 528 (1.3%) and 128 (2.7%) patients respectively. After propensity score weighting, treated patients had similar risks of all malignancies [weighted hazard ratio (wHR): 1.01, 95% CI: 0.82-1.25, P = 0.899], lung/pleural cancers (wHR: 0.82, 95% CI: 0.52-1.31, P = 0.409) and urinary/renal malignancies (wHR: 1.04, 95% CI: 0.38-2.81, P = 0.944) when compared with untreated patients. CONCLUSIONS: Oral nucleos(t)ide analogue treatment does not appear to increase cancer risk in patients with chronic hepatitis B. Given the beneficial effect on liver outcomes, our data support the current practice of long-term anti-viral therapy.
引用
- Wong GL, Tse YK, Yip TC, et al. Long-term use of oral nucleos(t)ide analogues for chronic hepatitis B does not increase cancer risk - a cohort study of 44 494 subjects. Aliment Pharmacol Ther. 2017. PMID: 28239880. doi:10.1111/apt.14015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。